Pancreatic cancer is associated with medication changes prior to clinical diagnosis

Yin Zhang, Qiao-Li Wang, Chen Yuan, Alice A. Lee, Ana Babic, Kimmie Ng, Kimberly Perez, Jonathan A. Nowak, Jesper Lagergren, Meir J. Stampfer, Edward L. Giovannucci, Chris Sander, Michael H. Rosenthal, Peter Kraft and Brian M. Wolpin ()
Additional contact information
Yin Zhang: Dana-Farber Cancer Institute and Harvard Medical School
Qiao-Li Wang: Dana-Farber Cancer Institute and Harvard Medical School
Chen Yuan: Dana-Farber Cancer Institute and Harvard Medical School
Alice A. Lee: Brigham and Women’s Hospital and Harvard Medical School
Ana Babic: Dana-Farber Cancer Institute and Harvard Medical School
Kimmie Ng: Dana-Farber Cancer Institute and Harvard Medical School
Kimberly Perez: Dana-Farber Cancer Institute and Harvard Medical School
Jonathan A. Nowak: Brigham and Women’s Hospital and Harvard Medical School
Jesper Lagergren: Karolinska University Hospital
Meir J. Stampfer: Harvard T. H. Chan School of Public Health
Edward L. Giovannucci: Harvard T. H. Chan School of Public Health
Chris Sander: Dana-Farber Cancer Institute
Michael H. Rosenthal: Brigham and Women’s Hospital and Harvard Medical School
Peter Kraft: Harvard T. H. Chan School of Public Health
Brian M. Wolpin: Dana-Farber Cancer Institute and Harvard Medical School

Nature Communications, 2023, vol. 14, issue 1, 1-10

Abstract: Abstract Patients with pancreatic ductal adenocarcinoma (PDAC) commonly develop symptoms and signs in the 1–2 years before diagnosis that can result in changes to medications. We investigate recent medication changes and PDAC diagnosis in Nurses’ Health Study (NHS; females) and Health Professionals Follow-up Study (HPFS; males), including up to 148,973 U.S. participants followed for 2,994,057 person-years and 991 incident PDAC cases. Here we show recent initiation of antidiabetic (NHS) or anticoagulant (NHS, HFS) medications and cessation of antihypertensive medications (NHS, HPFS) are associated with pancreatic cancer diagnosis in the next 2 years. Two-year PDAC risk increases as number of relevant medication changes increases (P-trend

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-38088-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38088-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-38088-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().